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Abstract Patients suffering from chronic mucocutaneous 
infections with the yeast Candida albicans (CMC) are dis­
cussed to have an underlying primary cellular immunodefi­
ciency. In order to characterise cellular immunity in CMC 
patients, we analysed chemotaxis and myeloperoxidase 
(MPO) releases of neutrophils and T cell proliferation and 
cytokine production to Candida albicans. Patients with 
chronic mucocutaneous candidiasis (n = 4) and healthy vol­
unteers of same sex and similar age (n = 14) were enrolled 
into the study. Neutrophil chemotaxis was assessed by 
transwell migration assay, and MPO release by ELISA. T 
cell proliferation capacity was investigated by thymidine 
incorporation and cytokine secretion in supernatants by 
ELISA. Neither neutrophil migration nor MPO release 
differed between CMC patients and healthy controls. The 
relative lymphocyte stimulation index (SI Candida/SI 
PHA) was heterogenous, but overall it was higher in CMC 
patients compared to controls. However, Candida-specific 
IFN-y production was significantly reduced in CMC 
patients. Notably, Candida-specific T cell IL-10 production 
was markedly higher in CMC patients. The inability to 
clear the yeast Candida albicans in our CMC patients does 
not seem to be due to an impaired neutrophil function or 
reduced antigen specific proliferation of lymphocytes. In
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fact, our patients tended to profiferate stronger to Candida 
antigen relative to PHA than healthy controls. However, the 
impaired Thl cytokine production with an enhanced IL-10 
production could play an important role in the pathogenesis 
of chronic mucocutaneous Candida infections.
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Introduction
Candida albicans is an ubiquitous opportunistic yeast, col­
onizing membranes of human skin and mucosal surfaces. 
The yeast causes infections (candidiasis) only, if the 
homeostasis between virulence of the microbe and resis­
tance of the host immune system is disturbed. A broad 
spectrum of candidiasis syndromes is known ranging from 
“simple” persistent paronychia and onychodystrophy over a 
complex group of disorders characterised by persistent or 
recurrent infections of the skin, nails and mucosal tissues 
(chronic mucocutaneous candidiasis—CMC) [16], to a 
recently described syndrome with concomitant polyendo- 
crinopathy and autosomal recessive inheritance (autoim­
mune polyendocrinopathy candidiasis ectodermal 
dystrophy syndrome—APECED) [11, 29]. The underlying 
defect of candidiasis syndromes may be a primary immune 
defect. This is the case in APECED, where a monogenic 
defect in the autoimmune regulator gene (AIRE) has been 
described [11], or in a form of dominant inherited CMC 
[18] with malfunction of the thyroid gland, where the 
underlying genetic defect has been mapped on chromosome 
2p [4]. However, the link between these mutations and the 
immune defect(s) remains unclear.
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Most of the studies in patients with chronic infection 
with candida conducted to date demonstrated an intact 
innate immunity [23]. Nevertheless, there are some studies 
suggesting a weakness in natural killer (NK) cells in CMC 
as either decreased [27, 28] or functionally impaired [12]. 
A subtle impairment of macrophage or monocyte [35] acti­
vation and migration due to an altered cytokine production 
has also been reported in some CMC patients [3, 16]. Con­
cerning neutrophil function, controversial studies have been 
published, describing a serum-dependent defect of neutro­
phil function [34] or a normal function [7].
Most of the CMC patients show normal humoral 
immune responses with normal serum concentrations of 
immunoglobulins and high titres of specific antibodies 
against Candida species [16, 20]. However, within the het­
erogeneous group of CMC patients, a small subgroup 
seems to suffer from recurrent respiratory infections accom­
panied by deficiency of the IgG subclasses 2 and 4 [5].
Protection against mucocutaneous Candida infections 
seems to rely mainly on cell-mediated immunity [6], partic­
ularly in T cells. Patients lacking T cells due to a severe 
combined immunodeficiency often suffer from this form of 
Candidiasis [15]. However, the ability of T cells to prolifer­
ate to Candida antigen is discussed controversially: while 
some studies describe a diminished proliferation both to 
Candida and to mitogens [12], other authors report sub­
groups of CMC patients with a Candida-specific defect or a 
normal response of T cells [14, 16, 35]. Recently, the cyto­
kine production of T cells has been the focus in numerous 
studies [12, 17, 20, 22, 23, 33], describing an altered cyto­
kine production with a diminished production of type-1 
cytokines such as IFN-y, IL-12 and IL-2 and an increased 
secretion of IL-10 or IL-4 [17].
The aim of this study was to elucidate possible dysfunc­
tions in cellular immune reactions in patients suffering from 
chronic Candida infections, focusing on neutrophil func­
tions on the one, and T cell proliferation and cytokine pro­
duction on the other hand, with a special emphasis on the 
Thl/Th2 balance in cellular immune response.
Materials and methods
Patients
Four patients were included into the study and compared 
with 19 healthy volunteers matched for sex and age. All 
patients were characterised both clinically and by several 
laboratory markers (Table 1). Before blood was taken, each 
participant gave his informed consent. The study was 
approved by the ethical committee of the Technical Univer­
sity Munich, following the guidelines of the Helsinki decla­
ration [1],
Neutrophil migration and phagocytosis capacity
In three patients (CMC1, CMC3, CMC4) human polymor­
phonuclear neutrophils (PMN) were isolated from total
Table 1 Clinical characteristics of patients enrolled in the study
Patient CMC1 CMC2 CMC3 CMC4
Age (years) 37 27 48 8
Sex ? ? ? J
Clinical symptoms Chronic oral, esophageal, vaginal and cutaneous candidiasis, 




Onset (at age) Early (4) Early (3) Early (birth) Early (3)
Endocrinology Normal Normal Normal Morbus Addison, 
polyendocrinopathy 
syndrome
Immunology Squamous cell 
carcinoma, ANA+







Iron deficiency anemia Normal Normal
Electrophoresis Albumin 56.9%4, Albumin 50.9%4, Albumin 55.9%4, Normal
y-globulin 22.0% f ^-globulin 22.8% f ^-globulin 20.4%f
Candida-Abs serum IgG <40 U/ml, IgG 258 U/ml, IgG 170 U/ml, IgG 47 U/ml,
IgM <60 U/ml IgM 1,172 U/ml IgM <60 U/ml IgM 96 U/ml
Immunoglobulins serum Normal Normal, IgG 40.20 g/14- IgG 1635 mg/dlf,
IgA 940 mg/dlf
Normal
Phenotyping of T cells Lymphopenia Normal Lymphopenia Lymphopenia
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blood by gradient centrifugation using Histopaque 1119 
(Sigma, Deisenhofen, Germany) as previously described 
[32]. PMN were resuspended in RPMI complete medium 
[RPMI 1,640 medium (Invitrogen, Paisley, Scotland) sup­
plemented with 2 mM L-glutamine, 1% nonessential amino 
acids, 1 mM sodium pyruvate (Invitrogen, Paisley, Scot­
land) and 0.05 mM 2-mercapto ethanol (Sigma, Deisenho­
fen, Germany)] with 5% bovine serum albumine (BSA; 
Sigma, Deisenhofen, Germany). Neutrophil chemotactic 
capacity was investigated by measuring migration through 
a 5 pm pore polycarbonate filter in 24 well chambers as 
previously reported [31, 32]. Briefly, PMN cells were 
added into the top chamber at a concentration of 
1 x  106 ml- 1 . LTB4 at a concentration of 1 x  10- 9  M or 
IL-8 at 300 pg/ml were added to the bottom chamber. After 
60 min, cell free supernatants were collected and immedi­
ately stored at —70°C until further analysis by ELISA. 
PMN that had transmigrated into the bottom chamber were 
counted by flow cytometry (FACScalibur, Becton Dickin­
son, Heidelberg, Germany). Results are shown as migration 
index, defined as ratio of migrated cells in the presence of a 
chemokine and migrated cells to medium alone.
Quantification of MPO in neutrophil supernatants was 
performed by ELISA according to manufacturer’s instruc­
tions (Assay Designs, Ann Arbor, MI, USA).
T cell proliferation and cytokine secretion
Peripheral blood mononuclear cells (PBMC) were sepa­
rated by centrifugation over Ficoll-Hyperpaque (Lympho­
prep, Progen biotech, Heidelberg, Germany). PBMC were 
cultured in RPMI complete medium (see above) with 5% 
human serum (Sigma, Deisenhofen, Germany). PBMC 
were stimulated for 60 h either with 1% phytohemaggluti­
nin (PHA) as positive control or with 10 mg/ml Candida 
albicans antigen (Allergopharma, Hamburg, Germany). 
Complete medium served as negative control. After 60 h, 
100 pl/well supernatant was obtained and stored at —70°C 
until further analysis by ELISA. Quantification of cytokines 
(IFN-y, IL-10 and IL-4) in supernatants was performed by 
ELISA according to the manufacturer’s instructions (BD, 
Heidelberg, Germany).
Cell proliferation was measured by [3H]thymidine incor­
poration. PBMC were incubated with 10 pCi/ml [3H]thymi- 
dine for 6 h  and then harvested on a filter. Counts per 
minute (cpm) were found by a ^-counter (Perkin Elmer, 
Rodgau, Germany). A stimulation index (SI) was calcu­
lated as ratio of cpm of stimulus (Candida or PHA) to cpm 
of medium control. A relative stimulation index (rSI) was 
calculated as ratio of SI Candida and SI PHA.
In another experimental set-up, PBMC of two CMC 
patients (CMC1 and CMC4) were left to adhere on petri 
dishes for 2 h at 37°C at a concentration of 6 x  106 ml- 1 .
The adherent cells (monocytes) were carefully detached 
and served as antigen presenting cells. The nonadherent 
fraction was separated into CD4+ and CD8+ T cells by pos­
itive selection using immunomagnetic beads coated with 
CD4 or CD8 antibody (Miltenyi, Bergisch Gladbach, Ger­
many), respectively. Monocytes (8 x  105 ml ’) and T cells 
(1 x  106 ml- 1 ) were incubated with PHA or Candida albi­
cans antigen for 60 h. Afterwards, proliferation and cyto­
kine production were analysed as described above.
Statistical analysis
Statistical analysis was performed by the software pro­
gramme SPSS 14.0. All results were analysed using a two­
sided students unpaired t-test. Statistically significant differ­
ences between CMC patients and controls were defined as 
p  < 0.05.
Results
Chemotactic and killing capacity of PMN in CMC patients
No significant difference to the matched controls was 
observed in neutrophil migration potency neither to LTB4 
nor to IL-8 as migration indices (MI) of PMN of CMC 
patients were comparable to MI of matched controls 
(Fig. 1).
Concerning the MPO release from PMN of CMC 
patients, no significant differences to the matched controls 
were detected (Fig. 1).
T cell proliferation
Proliferative capacity of CMC PBMC, as determined by the 
stimulation index (SI) to PHA, did not differ significantly 
between CMC patients and their matched controls (Fig. 2a). 
The relative stimulation index (SI Candida/PI PHA) was 
heterogenous in CMC patients (Fig. 2b). However, the 
difference between CMC patients and their controls was 
significant with a higher rSI of CMC patients (p = 0.04). 
Investigating T-cell subpopulations, a higher relative prolif­
eration to Candida albicans was observed also for CD4+ 
lymphocytes in the two tested patients (CMC1 and CMC4) 
with monocytes serving as antigen presenting cells, while 
CD8+ cells did not show a significant difference in the rela­
tive proliferation capacity (data not shown).
T cell cytokine secretion
In contrast to the proliferative capacity of T cells, which 
showed a trend to higher values, CMC patients showed a 
decreased secretion of the Thl cytokine IFN-y (Fig. 3a)
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Fig. 1 PMN effector functions 
of chronic mucocutaneous can­
didiasis (CMC) patients do not 
show significant differences to 
polymorphonuclear neutrophils 
(PMN) of matched controls, a, c 
Migration index (MI) and b, d 
myeloperoxidase (MPO) secre­
tion (ng/ml) by PMN stimulated 
withLTB4 (l x 10“9 M)orIL-8 
(300 pg/ml) of CMC patients 
and their corresponding controls 
(mean MI and mean MPO 
release ±  SEM)
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after mitogen stimulation and to a higher degree after spe­
cific stimulation with Candida antigen. T cells from CMC 
patients produced significantly lower amounts of IFN-y 
(p = 0,01) compared to their matched controls. Secretion of 
the Th2 cytokine IL-10 showed a distruct feature (Fig. 3B): 
while, after mitogen stimulation with PHA no difference 
was observed, concentrations of IL-10 were elevated in 
three out of four CMC patients after specific stimulation 
with Candida (p = 0,56). IL-4 secretion was under the 
detection limit of the ELISA. The difference in both IFN-y 
and IL-10 production was also observed when isolated 
CD4+ or CD8+ lymphocytes were stimulated with Candida 
albicans antigen with monocytes serving as antigen pre­
senting cells (data not shown).
Discussion
The underlying deficiencies of cellular immune responses 
in patients chronically infected with Candida albicans are 
controversially discussed. A complex heterogeneity of 
immune defect(s), probably characteristic for various sub­
groups, seems to be involved. In this study, we investigated 
neutrophil and T cellular function of four CMC patients. 
We found normal PMN effector functions, while the spe­
cific stimulation of T cells showed higher proliferation indi­
ces albeit impaired IFN-y secretion and a trend to a higher 
secretion of the inhibitory cytokine IL-10.
Several studies report a defect of the innate immunity 
leading to CMC [12, 27, 28, 35]. Therefore we investigated 
neutrophil effector functions in three out of four CMC 
patients. However, no significant difference was observed 
in migration capacity to LTB4 and to IL-8, suggesting that 
no general migration inability of the first line defence—the 
neutrophils—is substantial at least in our CMC patients. 
Notably, this kind of defect has been shown in two case 
reports of CMC patients with autoimmune or endocrinopa- 
thy dysfunctions [19, 25]. However, both reports docu­
mented a migration inability which was reversible by anti­
fungal therapy. Our experiments were performed before 
and after anti-fungal therapy without revealing any differ­
ences in the migration indices. Further effector functions of 
PMN were analysed by measuring MPO release into the 
supernatants of the migration experiments. Again, no sig­
nificant differences were detected in CMC patients com­
pared to controls. Notably, the interindividual difference in 
MPO release by neutrophils was enormous. Thus, it seems 
very difficult to estimate “abnormal” values or differences 
between CMC patients and controls in single case reports 
which might help to explain the controversial reports of 
increased [7] or decreased [19, 25] candidicidal capacity of 
neutrophils in CMC patients. Another hypothesis was put 
forward by a study describing a defect of neutrophil func­
tion dependent on autologous serum in CMC patients 
which was reversible by sufficient anti-fungal therapy, sug­
gesting that soluble factors may inhibit neutrophil functions 
[34],
Concerning the maximum T cell proliferation capacity 
tested by PHA-stimulation, no significant difference was 
observed between CMC patients and their matched controls 
with a huge interindividual difference in maximum stimula­
tion indices (SI). In order to be able to compare SI of differ-
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Fig. 2 Mucocutaneous candidiasis (CMC) patients do not generally 
suffer from a reduced T cell proliferation capacity, a The relative stim­
ulation index (SI Candida/ SI PHA) in % is shown for each CMC pa­
tient compared to the matched healthy controls. Mean rSI ±  SEM was 
higher in CMC patients, b Mean stimulation index to PHA (prolifera­
tion to PHA/proliferation to medium alone) of CMC patients was sim­
ilar to controls
ent individuals, we assumed the proliferation to PHA as 
maximum proliferation capacity of PBMC of the very 
patient and regarded the proliferation to the specific anti­
gen—Candida—relative to this proliferation. This allowed 
a more confident comparison of the SI between individuals. 
Therefore we applied the relative stimulation index as the 
ratio of the stimulation index to PHA and the response to 
Candida antigen. This rSI was higher in the CMC group 
compared to the corresponding controls. A possible expla­
nation for this higher immune response could be the boo- 
stering of the adaptive immune system when confronted 
with a chronic stimulus (in this case Candida albicans') [2]. 
This boostering effect is probably based on CD4+/CD29+/ 
CD45RO+ memory T cells, a cell population reported to be 
slightly decreased in CMC patients in one study [17]. How­
ever, our study reveals a higher relative T cell proliferation 
to Candida. Thus, a general decrease of specific T cell func­
tion does not seem to be responsible for the chronic infec-
Fig. 3 Impaired Thl cytokine secretion in mucocutaneous candidiasis 
(CMC) patients after Candida albicans stimulation. Concentrations are 
shown in pg/ml, mean secretion ±  SEM. a Interferon- y was signifi­
cantly reduced in the supernatant of PBMC of CMC patients compared 
to controls (p < 0,05). b Mean IL-10 secretion from PBMC stimulated 
with Candida was higher in CMC patients compared to controls 
(p > 0,05)
lions with Candida in our patients. An even more likely 
explanation for the inability to clear Candida albicans 
seems to be an altered rather than a diminished immune 
response of T cells. A dysregulated T cell cytokine produc­
tion has been described for other chronic infections, for 
example with human immunodeficiency virus [8-10], 
Leishmania braziliensis [30] and atypical mycobacteria 
[26],
In this study we have shown that CMC patients react to 
Candida, but not to PHA, with a lowered Thl response and 
with a higher production of the inhibitory cytokine IL-10. 
This observation is in concordance with several previous 
studies [13 ,17,21,24, 36 ,37]. However, the reason for this 
deviant cytokine production after Candida albicans stimu­
lation remains to be elucidated. In our study this phenome­
non of an impaired Thl response occurred also when 
antigen-specific proliferation assays were performed with 
purified CD4+ or CD8+ lymphocytes and monocytes as 
Antigen presenting cell (APC) in the presence of heterolo-
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gous human serum. This observation does not exclude a 
role of NK cells, B cells or cells of the innate immune sys­
tem in the immune-impotency towards candida albeit mak­
ing it more implausible to play a role in our patients. More 
likely, the higher specific immune response to Candida 
albicans observed in this study could ignite negative feed­
back mechanisms (e.g. via T regulatory cells) leading to an 
increased IL-10 production.
In summary, our data reveal normal neutrophil migration 
and MPO-releasing capacity in CMC patients. Relative pro­
liferation of T cells was higher to Candida, but showed an 
impaired Thl immune response and a higher production of 
the inhibitory cytokine IL-10. Whether this observation is a 
primary T cell dysfunction or the consequence of an abnor­
mality at the antigen presenting level in APC is open for 
discussion. With four CMC patients, the power of this 
study is, as in most studies concerning CMC, not high 
enough to draw general conclusions. Therefore, further 
studies with larger number of patients will be required for 
understanding the underlying mechanisms of this impaired 
Thl immune response in CMC patients.
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